Cargando…

Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2020 and coronavirus disease 19 (COVID-19) was later announced as pandemic by the World Health Organization (WHO). Since then, several studies have been conducted on the prevention and treatment of COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirtaleb, Mona Sadat, Mirtaleb, Amir Hossein, Nosrati, Hassan, Heshmatnia, Jalal, Falak, Reza, Zolfaghari Emameh, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Masson SAS. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962551/
https://www.ncbi.nlm.nih.gov/pubmed/33774315
http://dx.doi.org/10.1016/j.biopha.2021.111518
_version_ 1783665492624408576
author Mirtaleb, Mona Sadat
Mirtaleb, Amir Hossein
Nosrati, Hassan
Heshmatnia, Jalal
Falak, Reza
Zolfaghari Emameh, Reza
author_facet Mirtaleb, Mona Sadat
Mirtaleb, Amir Hossein
Nosrati, Hassan
Heshmatnia, Jalal
Falak, Reza
Zolfaghari Emameh, Reza
author_sort Mirtaleb, Mona Sadat
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2020 and coronavirus disease 19 (COVID-19) was later announced as pandemic by the World Health Organization (WHO). Since then, several studies have been conducted on the prevention and treatment of COVID-19 by potential vaccines and drugs. Although, the governments and global population have been attracted by some vaccine production projects, the presence of SARS-CoV-2-specific antiviral drugs would be an urge necessity in parallel with the efficient preventive vaccines. Various nonspecific drugs produced previously against other bacterial, viral, and parasite infections were recently evaluated for treating patients with COVID-19. In addition to therapeutic properties of these anti-COVID-19 compounds, some adverse effects were observed in different human organs as well. Not only several attentions were paid to antiviral therapy and treatment of COVID-19, but also nanomedicine, immunotherapy, and cell therapy were conducted against this viral infection. In this review study, we planned to introduce the present and potential future treatment strategies against COVID-19 and define the advantages and disadvantages of each treatment strategy.
format Online
Article
Text
id pubmed-7962551
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-79625512021-03-16 Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy Mirtaleb, Mona Sadat Mirtaleb, Amir Hossein Nosrati, Hassan Heshmatnia, Jalal Falak, Reza Zolfaghari Emameh, Reza Biomed Pharmacother Review Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2020 and coronavirus disease 19 (COVID-19) was later announced as pandemic by the World Health Organization (WHO). Since then, several studies have been conducted on the prevention and treatment of COVID-19 by potential vaccines and drugs. Although, the governments and global population have been attracted by some vaccine production projects, the presence of SARS-CoV-2-specific antiviral drugs would be an urge necessity in parallel with the efficient preventive vaccines. Various nonspecific drugs produced previously against other bacterial, viral, and parasite infections were recently evaluated for treating patients with COVID-19. In addition to therapeutic properties of these anti-COVID-19 compounds, some adverse effects were observed in different human organs as well. Not only several attentions were paid to antiviral therapy and treatment of COVID-19, but also nanomedicine, immunotherapy, and cell therapy were conducted against this viral infection. In this review study, we planned to introduce the present and potential future treatment strategies against COVID-19 and define the advantages and disadvantages of each treatment strategy. The Authors. Published by Elsevier Masson SAS. 2021-06 2021-03-16 /pmc/articles/PMC7962551/ /pubmed/33774315 http://dx.doi.org/10.1016/j.biopha.2021.111518 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Mirtaleb, Mona Sadat
Mirtaleb, Amir Hossein
Nosrati, Hassan
Heshmatnia, Jalal
Falak, Reza
Zolfaghari Emameh, Reza
Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
title Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
title_full Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
title_fullStr Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
title_full_unstemmed Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
title_short Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
title_sort potential therapeutic agents to covid-19: an update review on antiviral therapy, immunotherapy, and cell therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962551/
https://www.ncbi.nlm.nih.gov/pubmed/33774315
http://dx.doi.org/10.1016/j.biopha.2021.111518
work_keys_str_mv AT mirtalebmonasadat potentialtherapeuticagentstocovid19anupdatereviewonantiviraltherapyimmunotherapyandcelltherapy
AT mirtalebamirhossein potentialtherapeuticagentstocovid19anupdatereviewonantiviraltherapyimmunotherapyandcelltherapy
AT nosratihassan potentialtherapeuticagentstocovid19anupdatereviewonantiviraltherapyimmunotherapyandcelltherapy
AT heshmatniajalal potentialtherapeuticagentstocovid19anupdatereviewonantiviraltherapyimmunotherapyandcelltherapy
AT falakreza potentialtherapeuticagentstocovid19anupdatereviewonantiviraltherapyimmunotherapyandcelltherapy
AT zolfaghariemamehreza potentialtherapeuticagentstocovid19anupdatereviewonantiviraltherapyimmunotherapyandcelltherapy